Cart
sales@molnova.com
Quinolinic acid
CAS No. 89-00-9
Quinolinic acid( —— )
Catalog No. M19233 CAS No. 89-00-9
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 43 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 28 | In Stock |
|
Biological Information
-
Product NameQuinolinic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionQuinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway.
-
DescriptionQuinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway.
-
In VitroQuinolinic acid (0-50 mM; 24 hours) decreases the percentage of survival cells ranging from 100±0.01% at 5 mM to 45.23±0.01% at 50 mM in N18D3 cells. Cell Viability Assay Cell Line:N18D3 cells, hybrid neuronal cell line obtained by fusion of dorsal root ganglions isolated from 4-week-old Balb/C mouse with the mouse neuroblastoma N18TG2 cells Concentration:0, 10, 20, 30, 40, 50 mM Incubation Time:24 hoursResult:There was a corresponding decrease in the percentage of survival cells ranging from 100±0.01% at 5 mM to 45.23±0.01% at 50 mM.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorNMDA receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number89-00-9
-
Formula Weight173.17
-
Molecular FormulaC10H7NO2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 33.33 mg/mL 199.44 mM
-
SMILESOC(=O)c1cccnc1C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
24-Dihydroxypyrimidi...
24-Dihydroxypyrimidine-5-carboxylic acid (Uracil-5-carboxylic acid) has been obtained from 5-formyluracil by the action of enzyme thymine 7-hydroxylase. It has been used to synthesize N1-alkylated uracil derivatives.
-
NSC87877
NSC-87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively.
